(PJT) PJT Partners - Overview
Stock: Strategic Advisory, Capital Markets, Restructuring, Shareholder Advisory
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.63% |
| Yield on Cost 5y | 1.47% |
| Yield CAGR 5y | -25.23% |
| Payout Consistency | 86.0% |
| Payout Ratio | 14.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.2% |
| Relative Tail Risk | -7.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -23.59 |
| Character TTM | |
|---|---|
| Beta | 1.000 |
| Beta Downside | 0.905 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.25% |
| CAGR/Max DD | 0.97 |
Description: PJT PJT Partners January 07, 2026
PJT Partners Inc. (NYSE:PJT) is a boutique investment bank that delivers strategic, shareholder, capital-markets, and restructuring advisory services to corporations, sponsors, institutional investors, and governments worldwide. Its core offerings span M&A (including contested deals and spin-offs), activism defense, joint-venture structuring, debt and equity financing, IPOs, private placements, and geopolitical policy guidance. The firm also advises on liability management, distressed transactions, and provides private-fund fundraising and liquidity solutions for general and limited partners.
Key operating metrics (FY 2023) show total fee revenue of approximately $1.2 billion, with advisory fees representing roughly 70 % of the mix and a net profit margin near 17 %. PJT’s earnings are closely tied to macro drivers such as global M&A volume (which rose ~12 % YoY in 2023) and the level of corporate debt issuance, both of which tend to accelerate in a low-interest-rate environment but can contract sharply if rates rise sharply. The firm’s balance sheet remains strong, with a cash-to-debt ratio of 1.4×, providing flexibility to weather periods of reduced deal flow.
For a deeper quantitative view, you might explore PJT’s metrics on ValueRay to complement this high-level overview.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 53.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 3.39 > 1.0 |
| NWC/Revenue: 0.04% < 20% (prev 48.54%; Δ -48.50% < -1%) |
| CFO/TA 0.33 > 3% & CFO 566.3m > Net Income 53.49b |
| Net Debt (413.2m) to EBITDA (126.65b): 0.00 < 3 |
| Current Ratio: 9.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.79b) vs 12m ago 63.9k% < -2% |
| Gross Margin: 32.43% > 18% (prev 0.31%; Δ 3212 % > 0.5%) |
| Asset Turnover: 102.2k% > 50% (prev 91.31%; Δ 102.1k% > 0%) |
| Interest Coverage Ratio: -0.49 > 6 (EBITDA TTM 126.65b / Interest Expense TTM -229.62b) |
Altman Z'' 10.00
| A: 0.40 (Total Current Assets 771.8m - Total Current Liabilities 78.2m) / Total Assets 1.72b |
| B: 0.20 (Retained Earnings 336.9m / Total Assets 1.72b) |
| C: 67.55 (EBIT TTM 113.30b / Avg Total Assets 1.68b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 788.7m) |
| Altman-Z'' Score: 457.2 = AAA |
What is the price of PJT shares?
Over the past week, the price has changed by -6.79%, over one month by -9.66%, over three months by -2.94% and over the past year by -6.81%.
Is PJT a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PJT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 176.6 | 8.9% |
| Analysts Target Price | 176.6 | 8.9% |
| ValueRay Target Price | 194.3 | 19.8% |
PJT Fundamental Data Overview February 08, 2026
P/E Forward = 20.3252
P/S = 3.7683
P/B = 17.2796
P/EG = 1.36
Revenue TTM = 1713.67b USD
EBIT TTM = 113.30b USD
EBITDA TTM = 126.65b USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 413.2m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 413.2m USD (using Total Debt 413.2m, CCE unavailable)
Enterprise Value = 6.87b USD (6.46b + Debt 413.2m - (null CCE))
Interest Coverage Ratio = -0.49 (Ebit TTM 113.30b / Interest Expense TTM -229.62b)
EV/FCF = 12.79x (Enterprise Value 6.87b / FCF TTM 537.2m)
FCF Yield = 7.82% (FCF TTM 537.2m / Enterprise Value 6.87b)
FCF Margin = 0.03% (FCF TTM 537.2m / Revenue TTM 1713.67b)
Net Margin = 3.12% (Net Income TTM 53.49b / Revenue TTM 1713.67b)
Gross Margin = 32.43% ((Revenue TTM 1713.67b - Cost of Revenue TTM 1157.95b) / Revenue TTM)
Gross Margin QoQ = 32.43% (prev 32.16%)
Tobins Q-Ratio = 4.00 (Enterprise Value 6.87b / Total Assets 1.72b)
Interest Expense / Debt = 4.11% (Interest Expense 17.0m / Debt 413.2m)
Taxrate = 47.50% (162.79b / 342.70b)
NOPAT = 59.48b (EBIT 113.30b * (1 - 47.50%))
Current Ratio = 9.87 (Total Current Assets 771.8m / Total Current Liabilities 78.2m)
Debt / Equity = 1.81 (Debt 413.2m / totalStockholderEquity, two quarters ago 228.6m)
Debt / EBITDA = 0.00 (Net Debt 413.2m / EBITDA 126.65b)
Debt / FCF = 0.77 (Net Debt 413.2m / FCF TTM 537.2m)
Total Stockholder Equity = 183.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3189 % (out of range, set to none)
RoE = 29.2k% (out of range, set to none) (Net Income TTM 53.49b / Total Stockholder Equity 183.0m)
RoCE = 6905 % (out of range, set to none) (EBIT 113.30b / Capital Employed (Total Assets 1.72b - Current Liab 78.2m))
RoIC = 32.7k% (out of range, set to none) (NOPAT 59.48b / Invested Capital 181.6m)
WACC = 9.15% (E(6.46b)/V(6.87b) * Re(9.60%) + D(413.2m)/V(6.87b) * Rd(4.11%) * (1-Tc(0.48)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 27.66%
[DCF Debug] Terminal Value 76.91% ; FCFF base≈504.6m ; Y1≈595.6m ; Y5≈916.5m
Fair Price DCF = 503.8 (EV 12.66b - Net Debt 413.2m = Equity 12.25b / Shares 24.3m; r=9.15% [WACC]; 5y FCF grow 19.24% → 2.90% )
EPS Correlation: 70.77 | EPS CAGR: 28.35% | SUE: 0.53 | # QB: 0
Revenue Correlation: 54.31 | Revenue CAGR: 958.2% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.53 | Chg30d=+0.189 | Revisions Net=+2 | Analysts=6
EPS current Year (2026-12-31): EPS=7.80 | Chg30d=+0.190 | Revisions Net=+0 | Growth EPS=+11.8% | Growth Revenue=+10.3%
EPS next Year (2027-12-31): EPS=8.68 | Chg30d=+0.324 | Revisions Net=+2 | Growth EPS=+11.2% | Growth Revenue=+10.3%